Integral Health Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Integral Health Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100,000	Closed	-$4.86M	–	81
2025 Q2	$4.86M	Sell	100,000 -50,000	-33%	-$1.93M	0.45%	58
2025 Q1	$5.1M	Buy	+150,000	New	+$6.36M	0.54%	50
2024 Q4	–	Sell	-150,000	Closed	-$7.05M	–	86
2024 Q3	$7.05M	Hold	150,000	–	–	0.79%	35
2024 Q2	$8.1M	Sell	150,000 -70,000	-32%	-$4.05M	0.77%	42
2024 Q1	$15M	Buy	+220,000	New	+$15.7M	1.39%	29
2023 Q4	–	Sell	-275,000	Closed	-$12.5M	–	76
2023 Q3	$12.5M	Buy	275,000 +175,000	+175%	+$9.04M	1.73%	20
2023 Q2	$5.61M	Hold	100,000	–	–	0.7%	51
2023 Q1	$4.52M	Buy	+100,000	New	+$4.86M	0.91%	44
2022 Q4	–	Sell	-220,000	Closed	-$14.4M	–	71
2022 Q3	$14.4M	Buy	220,000 +139,990	+175%	+$10.1M	2.79%	9
2022 Q2	$4.86M	Sell	80,010 -39,990	-33%	-$2.35M	1%	35
2022 Q1	$7.53M	Buy	+120,000	New	+$7.54M	1.96%	17

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Integral Health Asset Management's CRSP Position: Q3 2025 in Review

Integral Health Asset Management sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 100,000 shares — an estimated $4.86M sold.

Integral Health Asset Management first reported a position in CRSP in Q1 2022 and held it in 11 quarters. The position peaked at $15M in Q1 2024. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

Integral Health Asset Management reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
Integral Health Asset Management sold 100,000 CRISPR Therapeutics shares in Q3 2025, an estimated $4.86M.
Integral Health Asset Management first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 11 quarters.
Integral Health Asset Management's CRISPR Therapeutics position peaked at $15M in Q1 2024.
440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Integral Health Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.